Research programme: phosphodiesterase 5 inhibitor - Chong Kun Dang PharmaceuticalAlternative Names: CKD-533
Latest Information Update: 16 Jul 2016
At a glance
- Originator Chong Kun Dang
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Erectile dysfunction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in South Korea (PO)